Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

The trial proposed here attempts to reduce induction chemotherapy to phase I of standard induction in patients with B-precursor ALL. Induction phase II will be replaced by blinatumomab.

dose reduced
blinatumomab
  • 0 views
  • 24 Jan, 2021
  • 27 locations
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT). HMCT refers to the infusion of donor peripheral

cellular therapy
cytopenias
stem cell transplantation
blinatumomab
gilbert's syndrome
  • 0 views
  • 14 Feb, 2021
  • 1 location
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

: The purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the

methotrexate
dexamethasone
hydroxyurea
conjugated bilirubin
tyrosine
  • 2 views
  • 15 Mar, 2021
  • 2 locations
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi

  • 0 views
  • 08 Apr, 2021
  • 78 locations
Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts

This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL The primary objective of this study is to determine if

lymphoblasts
philadelphia chromosome
blinatumomab
hysterectomy
tyrosine
  • 0 views
  • 26 Jan, 2021
  • 3 locations
Blinatumomab Inotuzumab Ozogamicin and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia

methotrexate
cytarabine
lymphoma
cyclophosphamide
vincristine
  • 0 views
  • 04 Mar, 2021
  • 1 location
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed Recurrent or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come

  • 3 views
  • 11 Apr, 2021
  • 189 locations
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back

filgrastim
cytarabine
methotrexate
cyclophosphamide
dexamethasone
  • 61 views
  • 24 Jan, 2021
  • 2 locations
Blinatumomab Methotrexate Cytarabine and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive or BCR-ABL Positive or Relapsed/Refractory Acute Lymphoblastic Leukemia

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute

methotrexate
cytarabine
serum bilirubin level
lipase
serum lipase
  • 29 views
  • 25 Jan, 2021
  • 2 locations
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B

  • 43 views
  • 11 Apr, 2021
  • 3 locations